1. Medtech Insight
  2. >>Business

US Approvals Analysis: Strong Q3 For Metabolic-Disease Devices

 
• By David Filmore

Of the five original PMAs approved last month by US FDA, two target diabetes and one targets obesity. In addition, the agency granted a de novo classification to another obesity device. Overall, FDA had a productive third-quarter for approvals and clearances.

FDA approved background, 3D rendering, blue street sign

[Editors' note: For sortable and searchable tables of all 2016 US and non-US approvals and clearances, check out our Approvals Tracker.]

Products addressing metabolic conditions attracted the most attention from US FDA's novel device approval pathways in September.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Business